SinoMab BioScience Limited
Research SinoMab BioScience Limited (3681.HK) on Bullrun: market cap HKD 1.53B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3681.HK
- ExchangeHK
- CountryHong Kong
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.53B
- Financial periodFY2025
- RevenueCNY 0
- Revenue growth-100.0%
- Net income-CNY 104.99M
- Free cash flow-CNY 95.78M
Valuation Snapshot
latest market cap is HKD 1.53B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 104.99M | -CNY 95.78M | n/a | -0.09 | CNY 322.71M | CNY 338.49M | CNY 507.88M |
| FY2024 | CNY 2.03M | -CNY 185.14M | -CNY 172.30M | 26.8% | -0.17 | CNY 61.90M | CNY 482.27M | CNY 192.91M |
| FY2023 | CNY 1.37M | -CNY 243.11M | -CNY 237.74M | 30.9% | -0.24 | CNY 203.66M | CNY 450.81M | CNY 295.58M |
| FY2022 | CNY 0 | -CNY 284.16M | -CNY 414.92M | n/a | -0.29 | CNY 345.71M | CNY 357.18M | CNY 509.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.53B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About SinoMab BioScience Limited
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SinoMab BioScience Limited's market cap?
SinoMab BioScience Limited's market capitalization is HKD 1.53B.
What does SinoMab BioScience Limited do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.